Xuelin Dou, Yuping Zhong, WanHong Zhao, Ling Qin, Xin Du, Aijun Liao, Zhongjun Xia, Chunyan Sun, Songfu Jiang, Dongping Huang, Haitang Xie, Liangming Ma, JiShi Wang, Fengyan Jin, Guifang Ouyang, Yanhong Tong, Min Dong, Bing Xu, Wenduo He, Shengli Cai, Jin Lu. "A first-in-human, phase I/II, open-label, multicenter, dose escalation and expansion study of lbl-034, a conditionally activated bispecific antibody targeting GPRC5D and CD3 with a 2:1 format, in patients with relapsed/refractory multiple myeloma." Blood, 2025. doi:10.1182/blood-2025-91